X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs DR. REDDYS LAB - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA DR. REDDYS LAB TORRENT PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 35.3 35.0 100.6% View Chart
P/BV x 5.3 2.7 198.3% View Chart
Dividend Yield % 1.0 1.0 101.6%  

Financials

 TORRENT PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
DR. REDDYS LAB
Mar-17
TORRENT PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,7683,397 52.0%   
Low Rs1,1862,560 46.3%   
Sales per share (Unadj.) Rs346.1856.5 40.4%  
Earnings per share (Unadj.) Rs55.278.0 70.8%  
Cash flow per share (Unadj.) Rs73.3139.9 52.4%  
Dividends per share (Unadj.) Rs14.0020.00 70.0%  
Dividend yield (eoy) %0.90.7 141.2%  
Book value per share (Unadj.) Rs257.1739.8 34.7%  
Shares outstanding (eoy) m169.22165.74 102.1%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.33.5 122.7%   
Avg P/E ratio x26.838.2 70.1%  
P/CF ratio (eoy) x20.121.3 94.6%  
Price / Book Value ratio x5.74.0 142.7%  
Dividend payout %25.425.7 98.9%   
Avg Mkt Cap Rs m249,887493,632 50.6%   
No. of employees `00011.822.7 51.9%   
Total wages/salary Rs m9,93431,068 32.0%   
Avg. sales/employee Rs Th4,971.56,259.0 79.4%   
Avg. wages/employee Rs Th843.21,369.8 61.6%   
Avg. net profit/employee Rs Th792.4569.7 139.1%   
INCOME DATA
Net Sales Rs m58,569141,961 41.3%  
Other income Rs m2,2331,715 130.2%   
Total revenues Rs m60,802143,676 42.3%   
Gross profit Rs m13,77324,722 55.7%  
Depreciation Rs m3,06910,266 29.9%   
Interest Rs m2,056634 324.2%   
Profit before tax Rs m10,88115,537 70.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5452,965 52.1%   
Profit after tax Rs m9,33612,921 72.3%  
Gross profit margin %23.517.4 135.0%  
Effective tax rate %14.219.1 74.4%   
Net profit margin %15.99.1 175.1%  
BALANCE SHEET DATA
Current assets Rs m53,84196,837 55.6%   
Current liabilities Rs m31,61284,199 37.5%   
Net working cap to sales %38.08.9 426.3%  
Current ratio x1.71.2 148.1%  
Inventory Days Days9773 132.5%  
Debtors Days Days8498 85.8%  
Net fixed assets Rs m42,079102,552 41.0%   
Share capital Rs m846829 102.1%   
"Free" reserves Rs m42,655121,792 35.0%   
Net worth Rs m43,501122,621 35.5%   
Long term debt Rs m22,4085,449 411.2%   
Total assets Rs m101,250218,165 46.4%  
Interest coverage x6.325.5 24.7%   
Debt to equity ratio x0.50 1,159.2%  
Sales to assets ratio x0.60.7 88.9%   
Return on assets %11.36.2 181.1%  
Return on equity %21.510.5 203.7%  
Return on capital %19.612.9 152.2%  
Exports to sales %054.6 0.0%   
Imports to sales %09.4 0.0%   
Exports (fob) Rs mNA77,520 0.0%   
Imports (cif) Rs mNA13,274 0.0%   
Fx inflow Rs m20,06681,670 24.6%   
Fx outflow Rs m5,30426,355 20.1%   
Net fx Rs m14,76255,315 26.7%   
CASH FLOW
From Operations Rs m10,12721,444 47.2%  
From Investments Rs m-7,869-18,404 42.8%  
From Financial Activity Rs m-1,918-3,692 52.0%  
Net Cashflow Rs m212-1,144 -18.5%  

Share Holding

Indian Promoters % 71.5 25.5 280.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 5.4 130.0%  
FIIs % 12.6 35.3 35.7%  
ADR/GDR % 0.0 18.5 -  
Free float % 8.8 15.3 57.5%  
Shareholders   26,511 75,885 34.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   SUN PHARMA  WYETH LTD  ABBOTT INDIA  UNICHEM LAB  MERCK LTD  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Extend Gains; Energy & PSU Stocks Rally(12:30 pm)

Stock markets in India continue to trade higher taking cues from their key Asian counterparts. Sectoral indices are trading in green with stocks in the oil & gas sector.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


May 28, 2018 02:47 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS